Increased expression of KCa3.1 has been found in atherosclerotic lesions from humans and mice [7,11] and several studies have shown systemic delivery of KCa3.1 inhibitors can attenuate atherosclerosis lesion development in mice [7,11–13]. Here, KCNN4 is linked to atherosclerosis.